期刊文献+

强直性脊柱炎中西医临床治疗进展 被引量:3

原文传递
导出
摘要 强直性脊柱炎(Ankylosing Spondylitis,AS)作为血清阴性脊柱关节病(Spondyloarthritis,SpA)的原型,其病理改变有肌腱端炎、骶髂关节炎、外周关节滑膜炎、眼色素膜炎等表现形式,其中最具特征性的病理改变为肌腱端炎。AS在我国患病率约0.3%,男女比2:1—3:1,以青壮年男性患者居多,病情进展常会导致脊柱畸形和强直,因此严重影响到患者的生活质量。目前中西医治疗AS各有所长,现就近几年来临床治疗现状及进展综述如下。
作者 王一荃 汪悦
出处 《湖南中医杂志》 2013年第10期151-153,共3页 Hunan Journal of Traditional Chinese Medicine
  • 相关文献

参考文献18

二级参考文献33

  • 1陆肇中.强直性脊柱炎的辨证论治体会[J].天津中医,1996,13(3):19-22. 被引量:31
  • 2王莉莎,黄烽,张江林,张莉芸,邓小虎,张亚美,李晓峰,郭军华.肿瘤坏死因子拮抗剂治疗类风湿关节炎和强直性脊柱炎发生结核的风险[J].中华风湿病学杂志,2006,10(10):607-610. 被引量:18
  • 3朱剑,黄烽,张莉芸,张江林,张奉春,候勇,余德恩.寻找预测强直性脊柱炎患者接受3次infliximab治疗后10周病情改善及复发的指标[J].中华风湿病学杂志,2007,11(5):288-292. 被引量:9
  • 4Bradley J R. TNF-mediated inflammatory disease [ J ]. J Pathol, 2008,214 ( 2 ) : 149 - 60.
  • 5Tracey D, Klareskog L, Sasso E H,et al. Tumor necrosis factor antagonist mechanisms of action : a comprehensive review [ J ]. Pharmacol Ther ,2008 ,117 ( 2 ) :244 -79.
  • 6Segal B, Rhodus N L,Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis[ J ]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod ,2008,106 (6) :778 -87.
  • 7Rosh J R, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale[ J] ? Inflamm Bowel Dis ,2007,13( 8 ) : 1024 - 30.
  • 8Mackey A C, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease : update[ J]. J Pediatr Gastroenterol Nutr,2009,48 ( 3 ) : 386 - 8.
  • 9Lindsley C W. Tumor necrosis factor (TNF) blockers ignite FDA inquiry over cancer concerns [ J ]. Curr Top Med Chem, 2008,8 (13) :1158.
  • 10Farrell R J, Ang Y, Kileen P, et al. Increased incidence of nonHodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is tow[ J ]. Gut,2000, 47(4) :514 -9.

共引文献204

同被引文献32

  • 1黄烽.应重视非甾体抗炎药对早期强直性脊柱炎的治疗价值[J].中国药物应用与监测,2006,3(6):1-4. 被引量:11
  • 2李国青,张育,顾健.三种NSAIDS对活动期强直性脊柱炎患者疼痛的疗效及安全性评价[J].中国疼痛医学杂志,2007,13(3):133-136. 被引量:8
  • 3Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis:a randomized clinical trial [J]. Arthritis Rheum, 2005,52(6) : 1756-1765.
  • 4Robey PG,Termine JD. Human bone cells In vitro[J].Calcif Tissue Int, 1985,37 (5) : 453-560.
  • 5Diarra D,Stolna M,Polzer K,et al. Dickkopfl is a master regula- tor of joint rem odeling[J]. Nat Med,2007,13(2): 156-163.
  • 6Vane JR. The fight against rheumatism: from willow bark to COX-I sparing drugs[J]. J Physiol Pharmacol, 2000,51(4 Pt 1): 573-586.
  • 7Radi Z A,Khan N K. Effects of eyelooxygenase inhibition on bone,tendon, and ligament healing[J]. Inflamm Res, 2005,54(9): 358-366.
  • 8Wittenberg R H,Pesehke [J],Botel 15. Heterotopic ossification after spinal cord injury. Epidemiology and risk factors[J]. J Bone Joint Surg (Br), 1992,74(2):215-218.
  • 9Blaekwell K A,Raisz L G,Pilbeam C C. Prostaglandins in bone:bad cop,good cop[J]. Trends Endoerinol Metab, 2010,21(5): 294-301.
  • 10Toom A,Arend A,Gunnarsson D,et al. Bone formation zones in heterotopie ossifications :histologie findings and increased expression of bone morphogenetic protein 2 and transforming growth factors beta2 and beta3[J]. Calcif Tissue Int, 2007,80(4): 259-267.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部